Phase II study of Durvalumab plus concurrent radiotherapy in unresectable locally advanced NSCLC
Researchers from Japan today reported that the first phase II study to evaluate the efficacy and safety of durvalumab and concurrent curative radiation therapy for PD-L1-positive unresectable locally advanced non-small cell ...
Aug 8, 2022
0
14